BHC(SH:600721)2023-04-11 16:00Financial Performance - The company achieved operating revenue of CNY 349.88 million in 2022, a year-on-year increase of 24.36% driven by new orders and accelerated project progress[19]. - New signed orders amounted to CNY 516 million, representing a growth rate of 39.84%, with pharmaceutical R&D orders at CNY 268 million, up 21.27%, and clinical service orders at CNY 248 million, up 67.57%[19]. - The net profit attributable to shareholders was CNY -34.75 million, a decrease of 158.09% compared to the previous year[19]. - The basic earnings per share for 2022 was CNY -0.0925, a decline of 157.99% from CNY 0.1595 in 2021[20]. - The total revenue for 2022 was 350 million yuan, representing a 24.36% increase from 281 million yuan in the previous year[32]. - The main business revenue for 2022 was CNY 346.37 million, up 24.54% from the previous year[58]. - The company reported a basic earnings per share and diluted earnings per share significantly lower than the previous year, reflecting the same factors affecting net profit[22]. Assets and Liabilities - The company's total assets at the end of 2022 were CNY 1.00 billion, an increase of 1.94% from CNY 982.31 million at the end of 2021[19]. - As of December 31, 2022, the total assets amounted to 1.001 billion yuan, with net assets of 667 million yuan[32]. - The company's net assets attributable to shareholders decreased by 2.10% to CNY 667.02 million from CNY 681.30 million in 2021[19]. - The total liabilities rose to CNY 334,306,129.32 in 2022 from CNY 296,060,953.02 in 2021, marking an increase of approximately 12.9%[200]. - The total equity attributable to shareholders decreased to CNY 667,023,483.46 in 2022 from CNY 681,303,920.51 in 2021, a decline of approximately 2.1%[200]. Cash Flow - The net cash flow from operating activities was CNY 53.18 million, reflecting a 53.15% increase compared to CNY 34.72 million in 2021[19]. - The operating cash flow net amount increased by 53.15% to CNY 53.18 million, driven by higher cash receipts from pharmaceutical research projects[54]. - The company's cash and cash equivalents increased by 56.22% to CNY 135,730.65 million compared to the previous period[78]. - The accounts receivable increased by 8.97% to CNY 19,352.18 million, primarily due to increased receivables from pharmaceutical R&D[78]. Research and Development - The company increased its R&D investment, leading to a rise in R&D expenses by 22.2312 million yuan[32]. - Research and development expenses surged by 423.36% to CNY 27.48 million, reflecting increased investment in pharmaceutical research[54]. - The company completed over 500 drug development applications, serving more than 50 of the top 100 pharmaceutical companies in China[31]. - The company has established five major technology platforms for drug formulation, enhancing its competitive edge in the market[50]. Market and Business Strategy - The CRO industry in China is projected to grow at a compound annual growth rate of approximately 26.5%, reaching a market size of 22.2 billion USD by 2024[39]. - The company is focusing on expanding its market presence through strategic partnerships and enhancing its service offerings in drug development and clinical trials[40]. - The company plans to enhance its integrated service capabilities through mergers and acquisitions or by building new businesses to meet the rising demand for one-stop services in the CRO industry[87]. - The company aims to become a leading domestic CRO/CDMO enterprise in the "pharmaceutical health" industry, focusing on enhancing core competencies through strategic cooperation and acquisitions[89]. Governance and Compliance - The company has conducted 9 board meetings and reviewed 47 proposals, ensuring compliance with governance standards and enhancing decision-making processes[99]. - The company has maintained a strong governance structure with experienced professionals in key management positions, ensuring effective oversight and strategic direction[110]. - The audit report confirmed that the financial statements fairly reflect the company's financial position as of December 31, 2022[187]. - The company has not reported any dissenting opinions from the board members regarding company matters during the year[115]. Social Responsibility and Environmental Initiatives - The company has committed to fulfilling its social responsibilities by strengthening safety management and environmental protection measures[38]. - The company invested 2.588 million CNY in environmental protection initiatives during the reporting period[138]. - The company implemented carbon reduction measures, successfully reducing CO2 equivalent emissions by 100 tons during the reporting period[141]. - The company actively participated in social welfare activities, including donations and fee reductions for merchants, and was involved in 5 national major science and technology projects[144].